Advances in the Diagnosis and Treatment of Pancreatic Cancer
Retrieved on:
Tuesday, January 18, 2022
Biomarker, Survival, Patient, TYMS, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Pancreatic cancer, BCAT1, KYNU, B3GNT3, Experimental Biology and Medicine, GLOBE, Department, Cancer, Metabolism, Publishing, LDHA, Society, Prognosis, Experimental biology, Fudan University, TCGA, GEO, Pharmaceutical industry, Medicine
Pancreatic cancer is characterized by an extremely poor prognosis and limited treatment options.Metabolic reprogramming has emerged a novel hallmark of cancers, including pancreatic cancer.
Key Points:
- Pancreatic cancer is characterized by an extremely poor prognosis and limited treatment options.Metabolic reprogramming has emerged a novel hallmark of cancers, including pancreatic cancer.
- Recent studies indicate that alterations in specific metabolic pathways in pancreatic cancer contribute to tumor growth, therapeutic resistance, and immune escape.
- Nonetheless, the role of metabolic genes in pancreatic cancer has not been elucidated.
- Dr. Wu and colleagues used theTCGA and GEO databases to discover differentially expressed metabolic genes (DEMGs) in pancreatic cancer.